Research Grade Tremelimumab ( 曲美木单抗 )
- 发布日期： 2020-10-28
- 更新日期： 2025-10-24
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00156
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
745013-59-6
|
| 保质期 |
一年
|
| 抗体名 |
Tremelimumab ( 曲美木单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
CTLA4/CD152[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
货号（Catalog No.）
CSD00156
通用名INN
Tremelimumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
别名(Alternative names)
CP-675,CP-675,206,CP-675206 clone 11.2.1
靶点;物种(Specificity target name;species)
CTLA4/CD152[Homo sapiens]
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG2-kappa
化学信息
CAS
745013-59-6
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
